MannKind Corporation (MNKD) fair value analysis

Nasdaq · Updated 2026-09-07

MannKind Corporation is a biopharmaceutical company that develops and commercializes therapies for patients with endocrine and genetic disorders. The company is based in the United States and operates in the healthcare sector, focusing on innovative treatment solutions for serious medical conditions.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, MNKD is trading at more than a 25% discount to estimated fair value.

MNKD currently ranks #17 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $3.80
Sector: Healthcare
12-month range: $2.54–$6.01

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Low
Margin trend: Expanding
Revenue growth: High
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The lower-middle quarter of its range
DCF cross-check: Overvalued

What our data shows for MNKD

Our model validated 6 trailing price-to-earnings windows for MNKD, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $2.54–$6.01.
The 14-day relative strength index sits at a neutral 50.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for MNKD
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent MNKD news

TickrTrends' derived news-sentiment signal for MNKD is currently leaning positive, computed from recent coverage.

MannKind: New Approvals Majorly Increase MannKind's Prospects (NASDAQ:MNKD) (seekingalpha.com, 2026-08-13)
TickrTrends take: MannKind operates in the Healthcare sector where regulatory approvals can meaningfully alter the commercial trajectory and financial prospects of a company. TickrTrends currently assesses MNKD as undervalued, which suggests the market may not yet be fully pricing in the potential revenue impact from expanded approvals. Investors focused on valuation should monitor whether these new approvals translate into revenue growth that validates or challenges the current undervalued assessment.
MannKind outlines $110M-$120M 2026 Furoscix revenue target as ReadyFlow ships in weeks (NASDAQ:MNKD) (seekingalpha.com, 2026-08-06)
TickrTrends take: MannKind's 2026 revenue guidance for Furoscix of 110 million to 120 million dollars represents a significant expansion opportunity for the company as ReadyFlow enters the market. Given TickrTrends' current undervalued assessment, investors monitoring the stock should track whether actual Furoscix adoption and ReadyFlow uptake align with this revenue target, as execution on these commercialization milestones could materially affect the company's valuation trajectory. The healthcare sector backdrop and near-term product launch timing make near-term revenue realization a key metric for validating the current undervalued positioning.
MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript (seekingalpha.com, 2026-08-06)
TickrTrends take: # MannKind Corporation Valuation Context MannKind Corporation released its Q2 2026 earnings call transcript, providing updated financial performance data that informs its current undervalued positioning according to TickrTrends analysis. For valuation-focused readers monitoring this Healthcare sector company, the earnings call offers insight into revenue trends, operating margins, and management guidance that support or challenge the undervalued assessment. Investors should examine whether the company's financial results and forward outlook justify the current valuation discount relative to comparable Healthcare peers.

What people are saying

Follow the MNKD conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is MNKD stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), MNKD is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is MNKD's TickrTrends verdict?

MNKD's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does MNKD compare to other Healthcare stocks?

MNKD ranks #17 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is MNKD overbought or oversold?

MNKD's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

MNKD vs AMPH · MNKD vs ANIP · MNKD vs COO · MNKD vs DXCM · MNKD vs HALO